Clinical trial
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic…
NCT00072085 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00072085 |
|---|---|
| Title | Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma |
| Official title | Immunization Of Patients With Metastatic Melanoma Using A Recombinant GP100 Protein (184V) And A Class I Restricted Peptide From The GP100 Antigen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, gp100 antigen, incomplete Freund's adjuvant |
| Start date | Sep 1, 2003 |
| Completion | Jul 1, 2006 |
| First posted | Nov 6, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: